EyePoint, Inc.
EyePoint, Inc. (EYPT) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Watertown, United States and has 214 employees. The company is worth $35.89M. Revenue was $31.37M in fiscal 2025, down 27.5% from the year before. It reported a net loss of $231.96M. The share price is 97.8% below its 52-week high of $19.11. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $28.28M. In that quarter, 2 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -81.1% over 5Y.
today you would have $260.68▼ -73.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 16 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $18.27 | $7.45 | $23.11 | $3.50 | $12.24 | $6.58 | $15.50 | $18.90 | $10.80 | $17.10 | $48.20 | $41.10 | $39.70 | $12.10 | $11.10 | $51.10 | |
| P/E | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CCELCryo Cell International Inc | $4.42 | — | — | 13.57% | — | $35.64M |
| LITSLite Strategy, Inc. | $1.19 | — | 0.9x | 0.00% | -243.02% | $36.18M |
| NNOXNano-X Imaging Ltd. | $0.45 | — | 0.4x | 0.00% | -98.98% | $35.59M |
| ATNMActinium Pharmaceuticals, Inc. | $1.13 |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| 23.0x |
| — |
| — |
| — |
| — |
| 11.1x |
| P/S | 10.4x | 48.6x | 11.8x | 25.0x | 2.9x | 11.3x | 5.5x | 9.5x | 39.4x | 5.6x | 36.1x | 5.3x | 34.7x | 49.6x | 8.0x | 4.6x | 4.2x |
| P/B | 3.8x | 5.0x | 1.5x | 4.3x | 1.2x | 2.3x | 10.2x | 23.2x | 4.8x | 3.2x | 2.8x | 6.1x | 8.1x | 13.8x | 2.1x | 0.6x | 2.9x |
| EPS | -$3.17 | -$2.32 | -$1.82 | -$2.74 | -$2.03 | -$3.54 | -$5.44 | -$12.70 | -$5.20 | -$6.80 | $2.10 | -$4.90 | -$5.20 | -$11.90 | -$4.40 | $4.60 |
| Profit margin | -262.92% | -739.42% | -302.43% | -153.84% | -246.97% | -158.14% | -131.82% | -278.88% | -1884.16% | -245.19% | -1330.06% | 23.89% | -384.54% | -555.30% | -704.34% | -173.78% | 37.97% |
| ROE | -96.34% | -75.78% | -38.89% | -26.58% | -106.11% | -31.68% | -244.83% | -681.79% | -228.85% | -138.61% | -103.19% | 27.16% | -89.49% | -154.55% | -182.13% | -23.05% | 26.49% |
Median of the years shown; P/E years above 200x are left out.
| 3.2x |
| 1.2x |
| 0.00% |
| 45.86% |
| $35.53M |
| IXHLIncannex Healthcare Inc. | $2.82 | — | 0.5x | 0.00% | -47.80% | $35.38M |
| SCYXScynexis Inc | $3.67 | — | 0.5x | 0.00% | -18.38% | $36.52M |